Histone Deacetylase Inhibitors as a Therapeutic Modality in Multiple Sclerosis

The Epigenetics of Autoimmune Diseases

Volumn , Issue , 2009, Pages 403-432

  Gray, Steven G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Histone citrullination; Histone deacetylase inhibitors; Multiple sclerosis (MS), causing neurological disability; Protein arginine methyltransferases (PRMTs); Regulator of matrixmetalloproteinases (RECK); Sp1 transcription factor; Stem cell neuronal differentiation

Indexed keywords

EID: 78649270522     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470743553.ch23     Document Type: Chapter

References (252)

1. Ragonese, P., Aridon, P., Salemi, G. et al. (2008) Mortality in multiple sclerosis: a review. European Journal of Neurology 15, 123-127.
2. Sobocki, P., Pugliatti, M., Lauer, K. et al. (2007) Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Multiple Sclerosis 13, 1054-1064.
3. Smith, L.T., Otterson, G.A. and Plass, C. (2007) Unraveling the epigenetic code of cancer for therapy. Trends in Genetics 23, 449-456.
4. Barlesi, F., Giaccone, G., Gallegos-Ruiz, M.I. et al. (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. Journal of Clinical Oncology 25, 4358-4364.
5. Pal, S. and Sif, S. (2007) Interplay between chromatin remodelers and protein arginine methyl-transferases. Journal of Cellular Physiology 213, 306-315.
6. Wang, Y., Wysocka, J., Sayegh, J. etal. (2004) Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306, 279-283.
7. Mastronardi, F.G., Wood, D.D., Mei, J. et al. (2006) Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. Journal of Neuroscience 26, 11387-11396.
8. Wood, D.D., Ackerley, C.A., Brand, B. et al. (2008) Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Laboratory Investigation 88, 354-364.
9. Mann, B.S., Johnson, J.R., Cohen, M.H. et al. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247-1252.
10. Sarkander, H.I., Fleischer-Lambropoulos, H. and Brade, W.P. (1975) A comparative study of histone acetylation in neuronal and glial nuclei enriched rat brain fractions. FEBS Letters 52, 40-43.
11. Liu, H., Hu, Q., Kaufman, A. etal. (2008) Developmental expression of histone deacetylase 11 in the murine brain. Journal of Neuroscience Research 86, 537-543.
12. Lakowski, B., Roelens, I. and Jacob, S. (2006) CoREST-like complexes regulate chromatin modification and neuronal gene expression. Journal of Molecular Neuroscience 29, 227-239.
13. Weaver, I.C., Cervoni, N., Champagne, F.A. et al. (2004) Epigenetic programming by maternal behavior. Nature Neuroscience 7, 847-854.
14. Renthal, W., Maze, I., Krishnan, V. et al. (2007) Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 56, 517-529.
15. Seth, K.A. and Majzoub, J.A. (2001) Repressor element silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) can act as an enhancer as well as a repressor of corticotropin-releasing hormone gene transcription. Journal of Biological Chemistry 276, 13917-13923.
16. Belyaev, N.D., Wood, I.C., Bruce, A.W. et al. (2004) Distinct RE-1 silencing transcription factor-containing complexes interact with different target genes. Journal of Biological Chemistry 279, 556-561.
17. Chen, Z.F., Paquette, A.J. and Anderson, D.J. (1998) NRSF/REST is required in vivo for repression of multiple neuronal target genes during embryogenesis. Nature Genetics 20, 136-142.
18. Paquette, A.J., Perez, S.E. and Anderson, D.J. (2000) Constitutive expression of the neuron-restrictive silencer factor (NRSF)/REST in differentiating neurons disrupts neuronal gene expression and causes axon pathfinding errors in vivo. Proceedings of the National Academy of Sciences USA 97, 12318-12323.
19. Bahn, S., Mimmack, M., Ryan, M. et al. (2002) Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study. Lancet 359, 310-315.
20. Thiel, G., Lietz, M. and Cramer, M. (1998) Biological activity and modular structure of RE-1-silencing transcription factor (REST), a repressor of neuronal genes. Journal of Biological Chemistry 273, 26891-26899.
21. Tapia-Ramirez, J., Eggen, B.J., Peral-Rubio, M.J. et al. (1997) A single zinc finger motif in the silencing factor REST represses the neural-specific type II sodium channel promoter. Proceedings of the National Academy of Sciences USA 94, 1177-1182.
22. Grimes, J.A., Nielsen, S.J., Battaglioli, E. et al. (2000) The co-repressor mSin3A is a functional component of the REST-CoREST repressor complex. Journal of Biological Chemistry 275, 9461-9467.
23. Huang, Y., Myers, S.J. and Dingledine, R. (1999) Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nature Neuroscience 2, 867-872.
24. Naruse, Y., Aoki, T., Kojima, T. etal. (1999) Neural restrictive silencer factor recruits mSin3 and histone deacetylase complex to repress neuron-specific target genes. Proceedings of the National Academy of Sciences USA 96, 13691-13696.
25. Roopra, A., Sharling, L., Wood, I.C. et al. (2000) Transcriptional repression by neuron-restrictive silencer factor is mediated via the SIN3-histone deacetylase complex. Molecular & CellularBiology 20, 2147-2157.
26. Andres, M.E., Burger, C., Peral-Rubio, M.J. et al. (1999) CoREST: a functional corepressor required for regulation of neural-specific gene expression. Proceedings of the NationalAcademy of Sciences USA 96, 9873-9878.
27. You, A., Tong, J.K., Grozinger, C.M. et al. (2001) CoREST is an integral component of the CoREST-human histone deacetylase complex. Proceedings of the National Academy of Sciences USA 98, 1454-1458.
28. Ballas, N., Grunseich, C., Lu, D.D. et al. (2005) REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121, 645-657.
29. Battaglioli, E., Andres, M.E., Rose, D.W. et al. (2002) REST repression of neuronal genes requires components of the hSWI.SNF complex. Journal of Biological Chemistry 277, 41038-41045.
30. Watanabe, H., Mizutani, T., Haraguchi, T. et al. (2006) SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 25, 470-479.
31. Wang, J., Scully, K., Zhu, X. etal. (2007) Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446, 882-887.
32. Horio, Y., Hisahara, S. and Sakamoto, J. (2003) Functional analysis of SIR2. Nippon Yakurigaku Zasshi 122 (suppl.), 30P-32P.
33. Kyrylenko, S., Kyrylenko, O., Suuronen, T. etal. (2003) Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cellular & Molecular Life Sciences 60, 1990-1997.
34. Ajamian, F., Suuronen, T., Salminen, A. et al. (2003) Upregulation of class II histone deacetylases mRNA during neural differentiation of cultured rat hippocampal progenitor cells. Neuroscience Letters 346, 57-60.
35. Hoshino, M., Tagawa, K., Okuda, T. etal. (2003) Histonedeacetylaseactivityisretainedinprimary neurons expressing mutant huntingtin protein. Journal of Neurochemistry 87, 257-267.
36. Brunet, A., Sweeney, L.B., Sturgill, J.F. et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015.
37. Linseman, D.A., Bartley, C.M., Le, S.S. et al. (2003) Inactivation of the myocyte enhancer factor-2 repressor histone deacetylase-5 by endogenous Ca(2 + )//calmodulin-dependent kinase II promotes depolarization-mediated cerebellar granule neuron survival. Journal of Biological Chemistry 278, 41472-41481.
38. Sharma, K., Sheng, H.Z., Lettieri, K. et al. (1998) LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons. Cell 95, 817-828.
39. Bach, I., Rodriguez-Esteban, C., Carriere, C. et al. (1999) RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex. Nature Genetics 22, 394-399.
40. Boutillier, A.L., Trinh, E. and Loeffler, J.P. (2002) Constitutive repression of E2F1 transcriptional activity through HDAC proteins is essential for neuronal survival. Annals of the New York Academy of Science 973, 438-442.
41. Konishi, Y. and Bonni, A. (2003) The E2F-Cdc2 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. Journal of Neuroscience 23, 1649-1658.
42. Hou, S.T., Callaghan, D., Fournier, M.C. etal. (2000) The transcription factor E2F1 modulates apoptosis of neurons. Journal of Neurochemistry 75, 91-100.
43. Wu, L., Timmers, C., Maiti, B. et al. (2001) The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414, 457-462.
44. Iglesias, A.H., Camelo, S., Hwang, D. etal. (2004) Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. Journal of Neuroim-munology 150, 163-177.
45. Camelo, S., Iglesias, A.H., Hwang, D. et al. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 164, 10-21.
46. Suzuki, T., Yokozaki, H., Kuniyasu, H. et al. (2000) Effect of trichostatin A on cell growth and expression of cell cycle-and apoptosis-related molecules in human gastric and oral carcinoma cell lines. International Journal of Cancer 88, 992-997.
47. Said, T.K., Moraes, R.C., Sinha, R. etal. (2001) Mechanisms ofsuberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Research 3, 122-133.
48. Dangond, F., Hafler, D.A., Tong, J.K. et al. (1998) Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochemical & Biophysical Research Communications 242, 648-652.
49. Ryu, H., Lee, J., Olofsson, B.A. et al. (2003) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proceedings of the National Academy of Sciences USA 100, 4281-4286.
50. Phiel, C.J., Zhang, F., Huang, E.Y. etal. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry276, 36734-36741.
51. Gottlicher, M., Minucci, S., Zhu, P. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal 20, 6969-6978.
52. Jeong, M.R., Hashimoto, R., Senatorov, V.V. et al. (2003) Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Letters 542, 74-78.
53. Humphrey, G.W., Wang, Y.H., Hirai, T. et al. (2007) Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells. Differentiation 76, 348-356.
54. Balasubramaniyan, V., Boddeke, E., Bakels, R. etal. (2006) Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells. Neuroscience 143, 939-951.
55. Lyssiotis, C.A., Walker, J., Wu, C. et al. (2007) Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proceedings of the National Academy of Sciences USA 104, 14982-14987.
56. Liu, A., Han, Y.R., Li, J. et al. (2007) The glial or neuronal fate choice of oligodendrocyte progenitors is modulated by their ability to acquire an epigenetic memory. Journal of Neuroscience 27, 7339-7343.
57. He, Y., Dupree, J., Wang, J. et al. (2007) The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. Neuron 55, 217-230.
58. Sun, G., Yu, R.T., Evans, R.M. et al. (2007) Orphan nuclear eceptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proceedings of the National Academy of Sciences USA 104, 15282-15287.
59. Su, X., Kameoka, S., Lentz, S. etal. (2004) Activation of REST/NRSF target genes in neural stem cells is sufficient to cause neuronal differentiation. Molecular & Cellular Biology 24, 8018-8025.
60. Greenway, D.J., Street, M., Jeffries, A. etal. (2007) RE1 silencing transcription factor maintains a repressive chromatin environment in embryonic hippocampal neural stem cells. Stem Cells 25, 354-363.
61. Sun, Y.M., Greenway, D.J., Johnson, R. etal. (2005) Distinct profiles of REST interactions with its target genes at different stages of neuronal development. Molecular Biology of the Cell 16, 5630-5638.
62. Gray, S.G. and Teh, B.T. (2001) Histone acetylation/deacetylation and cancer: an ''open'' and ''shut'' case? Current Molecular Medicine 1, 401-429.
63. Abbas, A.K., Murphy, K.M. and Sher, A. (1996) Functional diversity of helper T lymphocytes. Nature 383, 787-793.
64. O'garra, A. (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8, 275-283.
65. Chitnis, T. (2007) The role of CD4 T cells in the pathogenesis of multiple sclerosis. International Review of Neurobiology 79, 43-72.
66. Morinobu, A., Kanno, Y. and O'shea, J.J. (2004) Discrete roles for histone acetylation in human T helper 1 cell-specific gene expression. Journal of Biological Chemistry 279, 40640-40646.
67. Brogdon, J.L., Xu, Y., Szabo, S.J. etal. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109, 1123-1130.
68. Shi, Y., Feng, Y., Kang, J. et al. (2007) Critical regulation of CD4 + T cell survival and autoimmunity by beta-arrestin 1. Nature Immunology 8, 817-824.
69. Yamashita, M., Kuwahara, M., Suzuki, A. etal. (2008) Bm11 regulates memory CD4 T cell survival via repression of the Noxa gene. Journal of Experimental Medicine 205, 1109-1120.
70. Rott, O., Fleischer, B. and Cash, E. (1994) Interleukin-10 prevents experimental allergic encephalomyelitis in rats. European Journal of Immunology 24, 1434-1440.
71. Cua, D.J., Hutchins, B., Laface, D.M. et al. (2001) Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. Journal of Immunology 166, 602-608.
72. Laman, J.D., De Boer, M. and Hart, B.A. (1998) CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Developmental Immunology 6, 215-222.
73. Qin, H., Wilson, C.A., Lee, S.J. et al. (2005) LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 106, 3114-3122.
74. Qin, H., Wilson, C.A., Roberts, K.L. etal. (2006) IL-10 inhibits lipopolysaccharide-induced CD40 gene expression through induction of suppressor of cytokine signaling-3. Journal of Immunology 177, 7761-7771.
75. Kuchroo, V.K., Das, M.P., Brown, J.A. et al. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80, 707-718.
76. Leonard, J.P., Waldburger, K.E. and Goldman, S.J. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. Journal of Experimental Medicine 181, 381-386.
77. Bright, J.J., Musuro, B.F., Du, C. et al. (1998) Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. Journal of Neuroimmunology 82, 22-30.
78. Lu, J., Sun, H., Wang, X. et al. (2005) Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300. Cytokine 31, 46-51.
79. Dangond, F. and Gullans, S.R. (1998) Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochemical & Biophysical Research Communications 247, 833-837.
80. Saemann, M.D., Bohmig, G.A., Osterreicher, C.H. et al. (2000) Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB Journal 14, 2380-2382.
81. O'connor, K.C., Bar-or, A. and Hafler, D.A. (2001) The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. Journal of Clinical Immunology 21, 81-92.
82. Takahashi, I., Miyaji, H., Yoshida, T. etal. (1996) Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. Journal of Antibiotics 49, 453-457.
83. Matsuoka, H., Fujimura, T., Mori, H. etal. (2007) Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. International Immunopharmacology 7, 1422-1432.
84. Koyama, Y., Adachi, M., Sekiya, M. et al. (2000) Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 96, 1490-1495.
85. Matsuoka, H., Fujimura, T., Hayashi, M. etal. (2007) Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochemical Pharmacology 74, 465-476.
86. Tao, R., De Zoeten, E.F., Ozkaynak, E. et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Medicine 13, 1299-1307.
87. Li, B., Samanta, A., Song, X. et al. (2007) FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proceedings of the National Academy of Sciences USA 104, 4571-4576.
88. Gilbert, K.M. and Weigle, W.O. (1993) Th1 cell anergy and blockade in G1a phase of the cell cycle. Journal of Immunology 151, 1245-1254.
89. Gilbert, K.M., Wahid, R., Fecher, N.P. et al. (2000) Potential clinical use ofbutyric acid derivatives to induce antigen-specific T cell inactivation. Journal of Pharmacology and Experimental Therapeutics 294, 1146-1153.
90. Edens, R.E., Dagtas, S. and Gilbert, K.M. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. International Immunopharmacology 6, 1673-1681.
91. Kaneko, T., Hosokawa, H., Yamashita, M. et al. (2007) Chromatin remodeling at the Th2 cytokine gene loci in human type 2 helper T cells. Molecular Immunology 44, 2249-2256.
92. Kanazawa, S. and Peterlin, B.M. (2001) Combinations of dominant-negative class II transacti-vator, p300 or CDK9 proteins block the expression of MHC II genes. International Immunology 13, 951-958.
93. Fontes, J.D., Kanazawa, S., Jean, D. et al. (1999) Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Molecular & Cellular Biology 19, 941-947.
94. Masternak, K., Muhlethaler-Mottet, A., Villard, J. et al. (2000) CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes & Development 14, 1156-1166.
95. Raval, A., Howcroft, T.K., Weissman, J.D. etal. (2001) Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250. Molecular Cell 7, 105-115.
96. Masternak, K. and Reith, W. (2002) Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation. EMBO Journal 21, 1379-1388.
97. Zika, E., Greer, S.F., Zhu, X.S. et al. (2003) Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Molecular & Cellular Biology 23, 3091-3102.
98. Mckinsey, T.A., Kuwahara, K., Bezprozvannaya, S. et al. (2006) Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK. Molecular Biology of the Cell 17, 438-447.
99. Wang, A.H., Gregoire, S., Zika, E. et al. (2005) Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases. Journal of Biological Chemistry 280, 29117-29127.
100. Piskurich, J.F., Lin, K.I., Lin, Y. etal. (2000) BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nature Immunology 1, 526-532.
101. Ghosh, N., Gyory, I., Wright, G. et al. (2001) Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. Journal of Biological Chemistry 276, 15264-15268.
102. Chen, G., Fernandez, J., Mische, S. et al. (1999) A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. Genes & Development 13, 2218-2230.
103. Ren, B., Chee, K.J., Kim, T.H. et al. (1999) PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes & Development 13, 125-137.
104. Yu, J., Angelin-Duclos, C., Greenwood, J. et al. (2000) Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Molecular & Cellular Biology 20, 2592-2603.
105. Osborne, A., Zhang, H., Yang, W.M. etal. (2001) Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Molecular & Cellular Biology 21, 6495-6506.
106. Magner, W.J., Kazim, A.L., Stewart, C. etal. (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. Journal of Immunology 165, 7017-7024.
107. Brockmann, D., Lehmkuhler, O., Schmucker, U. et al. (2001) The histone acetyltransferase activity of PCAF cooperates with the brahma/SW12-related protein BRG-1 in the activation of the enhancer A of the MHC class I promoter. Gene 277, 111-120.
108. Williams, K., Ulvestad, E. and Antel, J.P. (1994) B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. European Journal of Immunology 24, 3031-3037.
109. Windhagen, A., Newcombe, J., Dangond, F. etal. (1995) Expressionofcostimulatorymolecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. Journal of Experimental Medicine 182, 1985-1996.
110. Genc, K., Dona, D.L. and Reder, A.T. (1997) Increased CD80 (+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. Journal of Clinical Investigation 99, 2664-2671.
111. Bohmig, G.A., Krieger, P.M., Saemann, M.D. et al. (1997) n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology 92, 234-243.
112. Zlokovic, B.V. (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
113. Yong, V.W., Zabad, R.K., Agrawal, S. et al. (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. Journal of the Neurological Sciences 259, 79-84.
114. Maeda, A. and Sobel, R.A. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. Journal of Neuropathology and Experimental Neurology 55, 300-309.
115. Fiorino, A.S. and Zvibel, I. (1996) Disruption of cell-cell adhesion in the presence of sodium butyrate activates expression of the 92 kDa type IV collagenase in MDCK cells. Cell Biology International 20, 489-499.
116. Kim, M.S., Son, M.W., Kim, W.B. et al. (2000) Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Letters 157, 23-30.
117. Vinodhkumar, R., Song, Y.S., Ravikumar, V. et al. (2007) Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chemico-biological Interactions 165, 220-229.
118. Aparicio, T., Kermorgant, S., Lewin, M.J. et al. (1998) Effects of HGF on the production of matrix metalloproteinases by colonic cancer cells DHD/K12. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 192, 311-315.
119. Liu, L.-T., Chang, H.-C., Chiang, L.-C. et al. (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Research 63, 3069-3072.
120. Pender, S.L., Quinn, J.J., Sanderson, I.R. et al. (2000) Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. American Journal of Physiology Gastrointestinal and Liver Physiology 279, G918-G924.
121. Nasu, Y., Nishida, K., Miyazawa, S. etal. (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16 (6), 723-732.
122. Emenaker, N.J. and Basson, M.D. (1998) Shortchainfattyacids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation. Journal of Surgical Research 76, 41-46.
123. Emenaker, N.J., Calaf, G.M., Cox, D. etal. (2001) Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. Journal of Nutrition 131 3041S-3046s.
124. Thelen, P., Schweyer, S., Hemmerlein, B. et al. (2004) Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. International Journal of Oncology 24, 25-31.
125. Gagnon, J., Shaker, S., Primeau, M. et al. (2003) Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs 14, 193-202.
126. Qian, X., Ara, G., Mills, E. et al. (2008) Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. International Journal of Cancer 122, 1400-1410.
127. Young, D.A., Billingham, O., Sampieri, C.L. et al. (2005) Differential effects of histone deacetylase inhibitors on phorbol ester-and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression. FEBS Journal 272, 1912-1926.
128. PerwezHussain, S. and Harris, C.C. (2007) Inflammation and cancer: an ancient link with novel potentials. International Journal of Cancer 121, 2373-2380.
129. Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436.
130. Qatanani, M. and Lazar, M.A. (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes & Development 21, 1443-1455.
131. Esiri, M.M. (2007) TheinterplaybetweeninflammationandneurodegenerationinCNSdisease. Journal of Neuroimmunology 184, 4-16.
132. Moenner, M., Pluquet, O., Bouchecareilh, M. et al. (2007) Integrated endoplasmic reticulum stress responses in cancer. Cancer Research 67, 10631-10634.
133. Eizirik, D.L., Cardozo, A.K. and Cnop, M. (2007) The role for endoplasmic reticulum stress in diabetes mellitus. Endocrine Reviews 29, 42-61.
134. Uehara, T. (2007) Accumulation of misfolded protein through nitrosative stress linked to neurodegenerative disorders. Antioxidants & Redox Signaling 9, 597-601.
135. Wei, H., Kim, S.J., Zhang, Z. et al. (2007) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Human Molecular Genetics 17, 469-477.
136. Gerritsen, M.E., Williams, A.J., Neish, A.S. et al. (1997) CREB-binding protein/p300 are transcriptional coactivators of p65. Proceedings of the National Academy of Sciences USA 94, 2927-2932.
137. Perkins, N.D., Felzien, L.K., Betts, J.C. et al. (1997) Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275, 523-527.
138. Wadgaonkar, R., Phelps, K.M., Haque, Z. et al. (1999) CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. Journal of Biological Chemistry 274, 1879-1882.
139. Sirianni, N., Naidu, S., Pereira, J. et al. (1998) Rett syndrome: confirmation of X-linked dominant inheritance, and localization of the gene to Xq28. American Journal of Human Genetics 63, 1552-1558.
140. Ashburner, B.P., Westerheide, S.D. and Baldwin, A.S. Jr. (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Molecular & Cellular Biology 21, 7065-7077.
141. Yeung, F., Hoberg, J.E., Ramsey, C.S. et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal 23, 2369-2380.
142. Hoberg, J.E., Popko, A.E., Ramsey, C.S. etal. (2006) IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Molecular & Cellular Biology 26, 457-471.
143. Hoberg, J.E., Yeung, F. and Mayo, M.W. (2004) SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Molecular Cell 16, 245-255.
144. Park, J., Lee, J.H., La, M. etal. (2007) Inhibition of NF-kappaB acetylation and its transcriptional activity by Daxx. Journal of Molecular Biology 368, 388-397.
145. Hollenbach, A.D., Mcpherson, C.J. Mientjes, E.J. et al. (2002) Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. Journal of Cell Science 115, 3319-3330.
146. Kuo, H.Y., Chang, C.C. Jeng, J.C. et al. (2005) SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proceedings of the National Academy of Sciences USA 102, 16973-16978.
147. Esposito, K., Nappo, F. Giugliano, F. etal. (2003) Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care 26, 1647.
148. Dandona, P., Aljada, A., Chaudhuri, A. etal. (2004) Endothelial dysfunction, inflammation and diabetes. Reviews in Endocrine & Metabolic Disorders 5, 189-197.
149. Dandona, P., Aljada, A. and Bandyopadhyay, A. (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology 25, 4-7.
150. Vanden Berghe, W., De Bosscher, K., Boone, E. et al. (1999) The nuclear factor-kappa B engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. Journal of Biological Chemistry 274, 32091-32098.
151. Bettelli, E., Dastrange, M. and Oukka, M. (2005) Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proceedings of the National Academy of Sciences USA 102, 5138-5143.
152. Kwon, H.K., So, J.S., Lee, C.G. et al. (2008) Foxp3 induces IL-4 gene silencing by affecting nuclear translocation of NFkappaB and chromatin structure. Molecular Immunology. 45, 3205-3212.
153. Miterski, B., Bohringer, S., Klein, W. etal. (2002) Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes and Immunity 3, 211-219.
154. Flores, N., Duran, C., Blasco, M.R. et al. (2003) NFkappaB and AP-1 DNA binding activity in patients with multiple sclerosis. Journal of Neuroimmunology 135, 141-147.
155. Satoh, J., Illes, Z., Peterfalvi, A. et al. (2007) Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neuroscience Letters 422, 30-33.
156. Ghosh, S., May, M.J. and Kopp, E.B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 16, 225-260.
157. Baldwin, Jr, A.S. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual Review of Immunology 14, 649-683.
158. Luhrs, H., Gerke, T., Boxberger, F. etal. (2001) Butyrateinhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells. Digestive Diseases and Sciences 46, 1968-1973.
159. Luhrs, H., Gerke, T., Schauber, J. et al. (2001) Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. International Journal of ColorectalDisease 16, 195-201.
160. Andoh, A., Fujiyama, Y., Shimada, M. et al. (2000) Modulation of complement component (C3 and factor B) biosynthesis by a histone deacetylase inhibitor in human intestinal epithelial cells. International Journal of Molecular Medicine 6, 51-54.
161. Andoh, A., Fujiyama, Y., Hata, K. etal. (1999) Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clinical and Experimental Immunology 118, 23-29.
162. Gibson, P.R., Rosella, O., Wilson, A.J. et al. (1999) Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis 20, 539-544.
163. Segain, J.P., Raingeard De La Bletiere, D., Bourreille, A. et al. (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47, 397-403.
164. Martin-Saavedra, F.M., Flores, N., Dorado, B. et al. (2007) Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis. Molecular Immunology 44, 3597-3607.
165. Van Loo, G., De Lorenzi, R., Schmidt, H. et al. (2006) Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nature Immunology 7, 954-961.
166. Hebert, D.N. and Molinari, M. (2007) In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiological Reviews 87, 1377-1408.
167. Rapoport, T.A. (2007) Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 450, 663-669.
168. Mhaille, A.N., Mcquaid, S., Windebank, A. et al. (2008) Increased expression of endoplasmic reticulum stress-related signaling pathway molecules in multiple sclerosis lesions. Journal of Neuropathology and Experimental Neurology 67, 200-211.
169. Lai, E., Teodoro, T. and Volchuk, A. (2007) Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology (Bethesda) 22, 193-201.
170. Caruso, M.E. and Chevet, E. (2007) Systems biology of the endoplasmic reticulum stress response. Subcellular Biochemistry 43, 277-298.
171. Ron, D. and Walter, P. (2007) Signalintegrationinthe endoplasmic reticulum unfolded protein response. Nature Reviews Molecular & Cellular Biology 8, 519-529.
172. Pahl, H.L. and Baeuerle, P.A. (1997) The ER-overload response: activation of NF-kappa B. Trends in Biochemical Sciences 22, 63-67.
173. Xu, C., Bailly-Maitre, B. and Reed, J.C. (2005) Endoplasmic reticulum stress: cell life and death decisions. Journal of Clinical Investigation 115, 2656-2664.
174. Rao, R.V., Ellerby, H.M. and Bredesen, D.E. (2004) Coupling endoplasmic reticulum stress to the cell death program. Cell Death & Differentiation 11, 372-380.
175. Bardag-Gorce, F., Dedes, J., French, B.A. et al. (2007) Mallory body formation is associated with epigenetic phenotypic change in hepatocytes in vivo. Experimental and Molecular Pathology 83, 160-168.
176. Hanada, S., Harada, M., Kumemura, H. etal. (2007) Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. Journal of Hepatology 47, 93-102.
177. Ohoka, N., Hattori, T., Kitagawa, M. et al. (2007) Critical and functional regulation of CHOP (C/EBP homologous protein) through the N-terminal portion. Journal of Biological Chemistry 282, 35687-35694.
178. Baumeister, P., Luo, S., Skarnes, W.C. etal. (2005) Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Molecular & Cellular Biology 25, 4529-4540.
179. Donati, G., Imbriano, C. and Mantovani, R. (2006) Dynamic recruitment of transcription factors and epigenetic changes on the ER stress response gene promoters. Nucleic Acids Research 34, 3116-3127.
180. Doody, G.M., Stephenson, S. and Tooze, R.M. (2006) BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. European Journal of Immunology 36, 1572-1582.
181. Rubenstein, R.C. and Zeitlin, P.L. (2000) Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. American Journal of Physiology Cellular Physiology 278, C259-C267.
182. Burrows, J.A., Willis, L.K. and Perlmutter, D.H. (2000) Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proceedings of the National Academy of Sciences USA 97, 1796-1801.
183. Qi, X., Hosoi, T., Okuma, Y. et al. (2004) Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Molecular Pharmacology 66, 899-908.
184. Vilatoba, M., Eckstein, C., Bilbao, G. et al. (2005) Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery 138, 342-351.
185. Mulhern, M.L., Madson, C.J., Kador, P.F. etal. (2007) Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Molecular Vision 13, 1397-1405.
186. Kubota, K., Niinuma, Y., Kaneko, M. et al. (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. Journal of Neurochemistry 97, 1259-1268.
187. Bonapace, G., Waheed, A., Shah, G.N. etal. (2004) Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proceedings of the National Academy of Sciences USA 101, 12300-12305.
188. Yam, G.H., Gaplovska-Kysela, K., Zuber, C. et al. (2007) Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Investigative Ophthalmology & Visual Science 48, 1683-1690.
189. Vij, N., Fang, S. and Zeitlin, P.L. (2006) Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleu-kin-8 levels: therapeutic implications. Journal of Biological Chemistry 281, 17369-17378.
190. Ozcan, U., Yilmaz, E., Ozcan, L. et al. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140.
191. De Almeida, S.F., Picarote, G., Fleming, J.V. et al. (2007) Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. Journal of Biological Chemistry 282, 27905-27912.
192. Wang, J.F., Bown, C. and Young, L.T. (1999) Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Molecular Pharmacology 55, 521-527.
193. Bown, C.D., Wang, J.F. and Young, L.T. (2000) Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment ofrat C6 glioma cells. Neuropharmacology 39, 2162-2169.
194. Chen, B., Wang, J.F. and Young, L.T. (2000) Chronicvalproatetreatmentincreasesexpressionof endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biological Psychiatry 48, 658-664.
195. Shao, L., Sun, X., Xu, L. et al. (2006) Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sciences 78, 1317-1323.
196. Wang, J.F., Azzam, J.E. and Young, L.T. (2003) Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 116, 485-489.
197. Shao, L., Young, L.T. and Wang, J.F. (2005) Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biological Psychiatry 58, 879-884.
198. Cui, J., Shao, L., Young, L.T. etal. (2007) Roleofglutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144, 1447-1453.
199. Kim, T.Y., Bang, Y.J. and Robertson, K.D. (2006) Histone deacetylase inhibitors for cancer therapy. Epigenetics 1, 14-23.
200. Mayo, M.W., Denlinger, C.E., Broad, R.M. et al. (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. Journal of Biological Chemistry 278, 18980-18989.
201. Liu, Y., Denlinger, C.E., Rundall, B.K. et al. (2006) Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. Journal of Biological Chemistry 281, 31359-31368.
202. Salminen, A., Tapiola, T., Korhonen, P. et al. (1998) Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Research Molecular Brain Research 61, 203-206.
203. Suuronen, T., Huuskonen, J., Pihlaja, R. et al. (2003) Regulation of microglial inflammatory response by histone deacetylase inhibitors. Journal of Neurochemistry 87, 407-416.
204. Adam, E., Quivy, V., Bex, F. et al. (2003) Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Molecular & Cellular Biology 23, 6200-6209.
205. Horion, J., Gloire, G., El Mjiyad, N. et al. (2007) Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappaB activation by delaying IkappaBalpha mRNA resynthesis: comparison with tumor necrosis factor alpha. Journal of Biological Chemistry 282, 15383-15393.
206. Kim, Y.K., Lee, E.K., Kang, J.K. et al. (2006) Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differentiation 13, 2033-2041.
207. Teckman, J.H. (2004) Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. Journal of Pediatric Gastroenterology and Nutrition 39, 34-37.
208. Nambiar, M.P., Warke, V.G., Fisher, C.U. etal. (2002) Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells ofpatients with systemic lupus erythematosus: a new mechanism for TCR zeta chain deficiency and abnormal signaling. Journal of Cellular Biochemistry 85, 459-469.
209. Mercuri, E., Bertini, E., Messina, S. etal. (2007) Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 68, 51-55.
210. Lezin, A., Gillet, N., Olindo, S. et al. (2007) Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 110, 3722-3728.
211. Kovacs, J.J., Murphy, P.J., Gaillard, S. et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Molecular Cell 18, 601-607.
212. Boyault, C., Gilquin, B., Zhang, Y. et al. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO Journal 25, 3357-3366.
213. Boyault, C., Zhang, Y., Fritah, S. etal. (2007) HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes & Development 21, 2172-2181.
214. Gao, Y.S., Hubbert, C.C., Lu, J. et al. (2007) Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Molecular & Cellular Biology 27, 8637-8647.
215. Fiskus, W., Ren, Y., Mohapatra, A. et al. (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clinical Cancer Research 13, 4882-4890.
216. Wang, Y., Wang, S.Y., Zhang, X.H. etal. (2007) FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochemical & Biophysical Research Communications 356, 998-1003.
217. Scroggins, B.T., Robzyk, K., Wang, D. etal. (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Molecular Cell 25, 151-159.
218. Edwards, A., Li, J., Atadja, P. et al. (2007) Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Molecular and Cancer Therapeutics 6, 2515-2524.
219. Bali, P., Pranpat, M., Bradner, J. etal. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function ofheat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. Journal of Biological Chemistry 280, 26729-26734.
220. Kong, X., Lin, Z., Liang, D. et al. (2006) Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Molecular & Cellular Biology 26, 2019-2028.
221. Johnson, C.A., White, D.A., Lavender, J.S. et al. (2002) Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. Journal of Biological Chemistry 277, 9590-9597.
222. Liu, X.L., Done, S.C., Yan, K. etal. (2004) Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. Journal of the American Society of Nephrology 15, 1731-1738.
223. Yam, G.H., Roth, J. and Zuber, C. (2007) 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality. Biochemical & Biophysical Research Communications 360, 375-380.
224. Datta, R., Waheed, A., Shah, G.N. etal. (2007) Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proceedings of the National Academy of Sciences USA 104, 19989-19994.
225. Watanabe, N. and Lam, E. (2007) BAX inhibitor-1 modulates endoplasmic reticulum stress-mediated programmed cell death in Arabidopsis. Journal of Biological Chemistry. 283, 3200-3210.
226. Zeitlin, P.L., Diener-West, M., Rubenstein, R.C. et al. (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Molecular Therapeutics 6, 119-126.
227. Singh, O.V., Vij, N., Mogayzel, P.J. Jr. et al. (2006) Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. Journal of Proteome Research 5, 562-571.
228. Rubenstein, R.C. and Zeitlin, P.L. (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. American Journal of Respiratory and Critical Care Medicine 157, 484-490.
229. Rubenstein, R.C. and Lyons, B.M. (2001) Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. American Journal of Physiology Lung Cellular and Molecular, Physiology 281, L43-L51.
230. Rubenstein, R.C., Egan, M.E. and Zeitlin, P.L. (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. Journal of Clinical Investigation 100, 2457-2465.
231. Lim, M., Mckenzie, K., Floyd, A.D. et al. (2004) Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. American Journal of Respiratory Cell and Molecular Biology 31, 351-357.
232. Kontopoulos, E., Parvin, J.D. and Feany, M.B. (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human Molecular Genetics 15, 3012-3023.
233. Choo-Kang, L.R. and Zeitlin, P.L. (2001) Induction of HSP70 promotes DeltaF508 CFTR trafficking. American Journal of PhysiologyLungCellular and Molecular, Physiology 281, L58-L68.
234. Cheong, N., Madesh, M., Gonzales, L.W. etal. (2006) Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. Journal of Biological Chemistry 281, 9791-9800.
235. Hayashi, H. and Sugiyama, Y. (2007) 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 45, 1506-1516.
236. Tveten, K., Holla, O.L., Ranheim, T. et al. (2007) 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. FEBS Journal 274, 1881-1893.
237. Kim, A.J., Shi, Y., Austin, R.C. etal. (2005) Valproateprotects cells from ERstress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. Journal of Cell Science 118, 89-99.
238. Corson, T.W., Woo, K.K., Li, P.P. et al. (2004) Cell-type specific regulation of calreticulin and Bcl-2 expression by mood stabilizer drugs. European Neuropsychopharmacology 14, 143-150.
239. Wang, J.F., Bown, C.D., Chen, B. et al. (2001) Identification of mood stabilizer-regulated genes by differential-display PCR. International Journal Neuropsychopharmacology 4, 65-74.
240. Kim, H.J., Rowe, M., Ren, M. et al. (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. Journal of Pharmacology and Experimental Therapeutics 321, 892-901.
241. Ren, M., Leng, Y., Jeong, M. et al. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles ofhistone deacetylase inhibition and heat shock protein induction. Journal of Neurochemistry 89, 1358-1367.
242. Morland, C., Boldingh, K.A., Iversen, E.G. et al. (2004) Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. Journal of Cerebral blood flow and Metabolism 24, 1226-1234.
243. Inden, M., Kitamura, Y., Takeuchi, H. et al. (2007) Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. Journal of Neurochemistry 101, 1491-1504.
244. Pan, T., Li, X., Xie, W. etal. (2005) Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Letters 579, 6716-6720.
245. Hiroi, T., Wei, H., Hough, C. etal. (2005) Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics Journal 5, 102-111.
246. Bevins, R.L. and Zimmer, S.G. (2005) It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Research 65, 6957-6966.
247. Spannhoff, A., Machmur, R., Heinke, R. et al. (2007) A novel arginine methyltransferase inhibitor with cellular activity. Bioorganic & Medicinal Chemistry Letters 17, 4150-4153.
248. Spannhoff, A., Heinke, R., Bauer, I. etal. (2007) Target-based approach to inhibitors of histone arginine methyltransferases. Journal of Medical Chemistry 50, 2319-2325.
249. Kubicek, S., O'sullivan, R.J., August, E.M. et al. (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Molecular Cell 25, 473-481.
250. Greiner, D., Bonaldi, T., Eskeland, R. et al. (2005) Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nature Chemical Biology 1, 143-145.
251. Cheng, D., Yadav, N., King, R.W. et al. (2004) Small molecule regulators of protein arginine methyltransferases. Journal of Biological Chemistry 279, 23892-23899.
252. Miao, F., Li, S., Chavez, V. et al. (2006) Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. Molecular Endocrinology 20, 1562-1573.